Development

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines. 


COVID-19: Shoring Up the Drug Delivery Infrastructure

Inovio received a $71-million contract from the US Department of Defense to scale up manufacture of its Cellectra smart device to deliver its DNA vaccine.

Inovio to Scale-Up Manufacture of Intradermal Delivery Device for its COVID-19 Vaccine

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab

The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.

TAE Life Sciences to Launch Drug Delivery Program After $30-Million Investment

Kindeva Drug Delivery plans capital investment and jobs growth.

Former 3M Drug Delivery Systems Launches as Kindeva Drug Delivery

With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.

Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform

Industry opportunities are increasing for biosimilars, but companies should pay close attention to delivery device design to facilitate success.


The Design Driver for Biosimilar Adoption

N4 Pharma will be undertaking a proof-of-concept research project using a COVID-19 DNA plasmid to demonstrate the ability of its delivery system, Nuvec, to collaborative partners developing DNA or RNA vaccines.

N4 Pharma Undertakes Research Project Using a COVID-19 DNA Plasmid

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.

On Point: Biologics Drive Growth in Pre-Filled Syringes

Jim Walter will take on the role of vice-president of operations for Catalent’s Oral and Specialty Delivery business. 